search
Back to results

Renal Denervation for Uncontrolled Hypertension (RDNP-2012-02)

Primary Purpose

Hypertension

Status
Withdrawn
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Renal Denervation
Sponsored by
Baker Heart and Diabetes Institute
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension focused on measuring renal denervation, blood pressure, cardiovascular risk, target organ damage, sympathetic activity

Eligibility Criteria

18 Years - 85 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • BP ≥140/90 mmHg (or ≥130/80 mmHg for patients with diabetes)
  • concurrent treatment with 2 anti-hypertensive drugs

Exclusion Criteria:

  • renal artery anatomy ineligible for treatment
  • eGFR <15mL/min/1.73m2 (using MDRD formula)
  • individual has had myocardial infarction, unstable angina or cerebrovascular accident within 6 months of screening visit
  • female participants of child bearing potential must have negative pregnancy test prior to treatment

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    No Intervention

    Experimental

    Arm Label

    Usual care

    Renal Denervation Group

    Arm Description

    participants randomised to the usual care group will receive additional antihypertensive medication in an attempt to achieve blood pressure targets

    participants randomised to undergo the renal denervation procedure

    Outcomes

    Primary Outcome Measures

    blood pressure control
    percentage of patients who achieve BP target at 6 months post intervention

    Secondary Outcome Measures

    number of drugs required to reach target blood pressure
    number of drugs required to reach target blood pressure
    time to achieve blood pressure target
    time to achieve blood pressure target
    change in sympathetic nerve activity
    changes in muscle sympathetic nerve activity (MSNA), renal and whole body Noradrenaline (NA) spillover
    Change in left ventricular function
    Change in left Ventricular ejection fraction, diastolic filling
    Change in Quality of Life
    Change in Quality of life as assessed be relevant questionnaires
    Change in Serum Biochemistry
    Plasma Renin Activity, aldosterone levels, estimated Glomerular Filtration Rate(eGFR), inflammatory markers, fasting glucose, fasting insulin, C-peptide, Homeostasis Model Assessment (HOMA) index, Lipid profile
    Change in markers of arterial stiffness
    Change in markers of arterial stiffness as assessed by Augmentation Index (AI) and Pulse Wave Velocity (PWV)
    Change in left ventricular structure
    Change in left ventricular mass index
    Change in Urine Biochemistry
    Urinary albumin creatinine ratio (UACR), 24 hour urinary creatinine clearance, sodium

    Full Information

    First Posted
    December 16, 2013
    Last Updated
    November 4, 2018
    Sponsor
    Baker Heart and Diabetes Institute
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02016573
    Brief Title
    Renal Denervation for Uncontrolled Hypertension
    Acronym
    RDNP-2012-02
    Official Title
    Renal Denervation for Uncontrolled Hypertension
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    November 2018
    Overall Recruitment Status
    Withdrawn
    Why Stopped
    No participants enrolled into study and protocol has been superseded
    Study Start Date
    December 2013 (Anticipated)
    Primary Completion Date
    April 2015 (Anticipated)
    Study Completion Date
    April 2015 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Baker Heart and Diabetes Institute

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    This is a study investigating the safety and usefulness of the Renal Denervation Procedure in reducing high blood pressure in people whose blood pressure is not adequately controlled despite already being treated with 2 blood pressure lowering drugs. This study is designed to compare the effects renal denervation to a usual care group.
    Detailed Description
    This is a phase 4 randomised control trial of renal denervation for the treatment of uncontrolled hypertension. Previous studies have shown that the renal denervation procedure is safe and effective in reducing blood pressure. A total of 100 participants with uncontrolled blood pressure, treated with two blood pressure lowering medications will be recruited into the study. Patients will be assigned to one of two groups. Participants in Group 1 will be assigned to undergo the renal denervation procedure. Participants in group 2 will undergo usual care, receiving additional antihypertensive medication in an attempt to reach blood pressure targets. The duration of this study is 36 months.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Hypertension
    Keywords
    renal denervation, blood pressure, cardiovascular risk, target organ damage, sympathetic activity

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    0 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Usual care
    Arm Type
    No Intervention
    Arm Description
    participants randomised to the usual care group will receive additional antihypertensive medication in an attempt to achieve blood pressure targets
    Arm Title
    Renal Denervation Group
    Arm Type
    Experimental
    Arm Description
    participants randomised to undergo the renal denervation procedure
    Intervention Type
    Device
    Intervention Name(s)
    Renal Denervation
    Other Intervention Name(s)
    Symplicity Renal Denervation Catheter
    Intervention Description
    Renal Denervation Catheter
    Primary Outcome Measure Information:
    Title
    blood pressure control
    Description
    percentage of patients who achieve BP target at 6 months post intervention
    Time Frame
    6 months post procedure
    Secondary Outcome Measure Information:
    Title
    number of drugs required to reach target blood pressure
    Description
    number of drugs required to reach target blood pressure
    Time Frame
    baseline to 6 months
    Title
    time to achieve blood pressure target
    Description
    time to achieve blood pressure target
    Time Frame
    baseline to 6 months
    Title
    change in sympathetic nerve activity
    Description
    changes in muscle sympathetic nerve activity (MSNA), renal and whole body Noradrenaline (NA) spillover
    Time Frame
    baseline to 6 months
    Title
    Change in left ventricular function
    Description
    Change in left Ventricular ejection fraction, diastolic filling
    Time Frame
    baseline to 6 months
    Title
    Change in Quality of Life
    Description
    Change in Quality of life as assessed be relevant questionnaires
    Time Frame
    baseline to 6 months
    Title
    Change in Serum Biochemistry
    Description
    Plasma Renin Activity, aldosterone levels, estimated Glomerular Filtration Rate(eGFR), inflammatory markers, fasting glucose, fasting insulin, C-peptide, Homeostasis Model Assessment (HOMA) index, Lipid profile
    Time Frame
    baseline to 6 months
    Title
    Change in markers of arterial stiffness
    Description
    Change in markers of arterial stiffness as assessed by Augmentation Index (AI) and Pulse Wave Velocity (PWV)
    Time Frame
    baseline to 6 months
    Title
    Change in left ventricular structure
    Description
    Change in left ventricular mass index
    Time Frame
    baseline to 6 months
    Title
    Change in Urine Biochemistry
    Description
    Urinary albumin creatinine ratio (UACR), 24 hour urinary creatinine clearance, sodium
    Time Frame
    baseline to 6 months

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    85 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: BP ≥140/90 mmHg (or ≥130/80 mmHg for patients with diabetes) concurrent treatment with 2 anti-hypertensive drugs Exclusion Criteria: renal artery anatomy ineligible for treatment eGFR <15mL/min/1.73m2 (using MDRD formula) individual has had myocardial infarction, unstable angina or cerebrovascular accident within 6 months of screening visit female participants of child bearing potential must have negative pregnancy test prior to treatment
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Markus P Schlaich, MD
    Organizational Affiliation
    Baker IDI Heart & Diabetes Institute
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No
    IPD Sharing Plan Description
    No data available

    Learn more about this trial

    Renal Denervation for Uncontrolled Hypertension

    We'll reach out to this number within 24 hrs